{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:55:49Z","timestamp":1794642949581,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The US President Malaria Initiatives,USAID"},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania. Unfortunately, there have been reports of artemisinin resistance and ACT failure from South East Asia highlighting the need to monitor therapeutic efficacy of ACT in these countries as recommended by World Health Organization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Open-label single arm studies in mainland Tanzania were conducted in nine sentinel sites in 2011, 2012 and 2015 to assess the efficacy and safety of artemether\/lumefantrine (AL) and artesunate\/amodiaquine (ASAQ) using 28\u00a0days follow-up and dihydroartemisinin\/piperaquine (DHAPQ) using 42\u00a0days follow-up. Mutations in the propeller domain of the <jats:italic>Plasmodium falciparum kelch 13<\/jats:italic> (<jats:italic>k13<\/jats:italic>) gene and amplification of the <jats:italic>P. falciparum plasmepsin 2<\/jats:italic> (<jats:italic>pm2<\/jats:italic>) gene, associated with artemisinin and piperaquine (PQ) resistance, were also investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 428 patients enrolled, 328 patients provided study endpoint. For AL, the PCR corrected per-protocol analysis showed adequate clinical and parasitological response (ACPR) of 90.3% (n\u2009=\u200928; 95% CI 74.2\u201398.0) in Kyela 2012, 95.7% (n\u2009=\u200922; 95% CI 78.1\u201399.0) in Chamwino, 100% in Muheza (n\u2009=\u200929; 95% CI 88.1\u2013100), 100% in Nagaga (n\u2009=\u200939; 95% CI 91.0\u2013100) and Kyela 2015 (n\u2009=\u200960; 95% CI 94.0\u2013100). For ASAQ, PCR corrected ACPR of 98% (n\u2009=\u200949; 95% CI 89.4\u201399.9) and 100% (n\u2009=\u200925; 95% CI 86.3\u2013100) were observed in 2011 in Ujiji and Kibaha, respectively. For DHAPQ, the ACPR was 100% (n\u2009=\u200971; 95% CI 94.9\u2013100). Of the 235 samples with genetic interpretable results, only 7 (3%) had non-synonymous <jats:italic>k13<\/jats:italic> mutations. None of these are candidate or validated markers of artemisinin resistance and all patients carrying these alleles cleared the parasites on day 3. Of the DHAPQ group, 10% (3\/29) of the samples with interpretable results had <jats:italic>pm2<\/jats:italic> multiple copies and none of them was associated with treatment failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>All the tested ACT in mainland Tanzania were highly efficacious and none of validated <jats:italic>k13<\/jats:italic> mutants associated with artemisinin resistance was observed. However, three isolates with multiple copy numbers of <jats:italic>pm2<\/jats:italic> gene associated with PQ resistance among the limited samples tested successfully calls for further investigation.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Number ACTRN12615000159550. Registered 18th February 2015, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/trial\/MyTrial.aspx\">https:\/\/www.anzctr.org.au\/trial\/MyTrial.aspx<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-018-2524-x","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T07:25:42Z","timestamp":1539761142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"actrn12615000159550","registry":"10.18810\/anzctr"}],"author":[{"given":"Mwaka A.","family":"Kakolwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhidin K.","family":"Mahende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deus S.","family":"Ishengoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine I.","family":"Mandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Ngasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Kamugisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes B.","family":"Kataraihya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Mandike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigsbert","family":"Mkude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Chacky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritha","family":"Njau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zul","family":"Premji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha M.","family":"Lemnge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdunoor M.","family":"Kabanywanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"2524_CR1","volume-title":"World malaria report 2017","author":"WHO","year":"2017","unstructured":"WHO. World malaria report 2017. Geneva: World Health Organization; 2017."},{"key":"2524_CR2","unstructured":"MOH. Tanzania Ministry of Health and Social Welfare. National guidelines for diagnosis and treatment of malaria; 2006."},{"key":"2524_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"2524_CR4","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin\u2013piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"2524_CR5","volume-title":"Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010","author":"WHO","year":"2010","unstructured":"WHO. Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"2524_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-015-0649-8","volume":"14","author":"A Shayo","year":"2015","unstructured":"Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malar J. 2015;14:135.","journal-title":"Malar J"},{"key":"2524_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12936-015-0918-6","volume":"14","author":"M Ndounga","year":"2015","unstructured":"Ndounga M, Mayengue PI, Casimiro PN, Koukouikila-Koussounda F, Bitemo M, Matondo BD, et al. Artesunate\u2013amodiaquine versus artemether\u2013lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10\u00a0years old living in a suburban area: a randomized study. Malar J. 2015;14:423.","journal-title":"Malar J"},{"key":"2524_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12936-015-0701-8","volume":"14","author":"R Dambe","year":"2015","unstructured":"Dambe R, Sande J, Ali D, Chilima B, Dodoli W, Michelo C, et al. Monitoring the efficacy of artemether\u2013lumefantrine for the treatment of uncomplicated malaria in Malawian children. Malar J. 2015;14:175.","journal-title":"Malar J"},{"key":"2524_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12936-016-1444-x","volume":"15","author":"M de Wit","year":"2016","unstructured":"de Wit M, Funk AL, Moussally K, Nkuba DA, Siddiqui R, Bil K, et al. In vivo efficacy of artesunate\u2013amodiaquine and artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo. Malar J. 2016;15:455.","journal-title":"Malar J"},{"key":"2524_CR10","doi-asserted-by":"publisher","first-page":"e0154618","DOI":"10.1371\/journal.pone.0154618","volume":"11","author":"D Nega","year":"2016","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y, et al. Therapeutic efficacy of artemether\u2013lumefantrine (Coartem\u00ae) in treating uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS ONE. 2016;11:e0154618.","journal-title":"PLoS ONE"},{"key":"2524_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2875-13-33","volume":"13","author":"BR Ogutu","year":"2014","unstructured":"Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, et al. Efficacy and safety of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J. 2014;13:33.","journal-title":"Malar J"},{"key":"2524_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-016-1281-y","volume":"15","author":"M Paczkowski","year":"2016","unstructured":"Paczkowski M, Mwandama D, Marthey D, Luka M, Makuta G, Sande J, et al. In vivo efficacy of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014. Malar J. 2016;15:236.","journal-title":"Malar J"},{"key":"2524_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/1475-2875-13-430","volume":"13","author":"B Hamainza","year":"2014","unstructured":"Hamainza B, Masaninga F, Moonga H, Mwenda M, Chanda-kapata P, Chalwe V, et al. Therapeutic efficacy of artemether\u2013lumefantrine on treatment of uncomplicated Plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia. Malar J. 2014;13:430.","journal-title":"Malar J"},{"key":"2524_CR14","doi-asserted-by":"publisher","first-page":"e113311","DOI":"10.1371\/journal.pone.0113311","volume":"9","author":"A Yeka","year":"2014","unstructured":"Yeka A, Lameyre V, Afizi K, Fredrick M, Lukwago R, Kamya MR, et al. Efficacy and safety of fixed-dose artesunate\u2013amodiaquine vs. artemether\u2013lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. PLoS ONE. 2014;9:e113311.","journal-title":"PLoS ONE"},{"key":"2524_CR15","doi-asserted-by":"publisher","first-page":"e0161495","DOI":"10.1371\/journal.pone.0161495","volume":"11","author":"J Ursing","year":"2016","unstructured":"Ursing J, Rombo L, Rodrigues A, Kofoed P-E. Artemether\u2013lumefantrine versus dihydroartemisinin\u2013piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in children aged less than 15\u00a0years in Guinea-Bissau\u2014an open-label non-inferiority randomized clinical trial. PLoS ONE. 2016;11:e0161495.","journal-title":"PLoS ONE"},{"key":"2524_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria in Cambodia. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"2524_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"2524_CR18","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"2524_CR19","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2010","unstructured":"WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2010."},{"key":"2524_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/1475-2875-12-405","volume":"12","author":"L Canier","year":"2013","unstructured":"Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for moving malaria PCR detection of parasite reservoir into the field. Malar J. 2013;12:405.","journal-title":"Malar J"},{"key":"2524_CR21","volume-title":"Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations","author":"WHO","year":"2008","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008."},{"key":"2524_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2875-12-103","volume":"12","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether\u2013lumefantrine tolerance\/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.","journal-title":"Malar J"},{"key":"2524_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4269\/ajtmh.2011.11-0071","volume":"85","author":"TT Thomsen","year":"2011","unstructured":"Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, et al. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Am J Trop Med Hyg. 2011;85:979\u201383.","journal-title":"Am J Trop Med Hyg"},{"key":"2524_CR24","first-page":"45","volume":"26","author":"D Sow","year":"2016","unstructured":"Sow D, Ndiaye JL, Sylla K, Ba MS, Tine RCK, Faye B, et al. Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate\u2013amodiaquine, dihydroartemisinin\u2013piperaquine, and artemether\u2013lumefantrine. Med Sante Trop. 2016;26:45\u201350.","journal-title":"Med Sante Trop"},{"key":"2524_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4269\/ajtmh.15-0826","volume":"97","author":"BK Abuaku","year":"2017","unstructured":"Abuaku BK, Mensah BA, Ofori MF, Myers-Hansen J, Derkyi-Kwarteng AN, Essilfie F, et al. Efficacy of artesunate\/amodiaquine in the treatment of uncomplicated malaria among children in Ghana. Am J Trop Med Hyg. 2017;97:690\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"2524_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/cid\/ciu353","volume":"59","author":"H Wanzira","year":"2014","unstructured":"Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo M, Conrad M, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether\u2013lumefantrine versus dihydroartemisinin\u2013piperaquine for the treatment of malaria. Clin Inf Dis. 2014;59:509\u201316.","journal-title":"Clin Inf Dis"},{"key":"2524_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1475-2875-12-254","volume":"12","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, et al. A randomized trial of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malar J. 2013;12:254.","journal-title":"Malar J"},{"key":"2524_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1128\/AAC.04181-14","volume":"59","author":"MM Plucinski","year":"2015","unstructured":"Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine for treatment of uncomplicated malaria in children in Zaire and U\u00edge provinces, Angola. Antimicrob Agents Chemother. 2015;59:437\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"2524_CR29","volume-title":"Artemisinin and artemisinin-based combination therapy resistance","author":"WHO","year":"2017","unstructured":"WHO. Artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2017."},{"key":"2524_CR30","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D Menard","year":"2016","unstructured":"Menard D, Khim N, Beghain J, Adegnika A, Shafiul-Alam M, Amodu O, et al. A world wide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med."},{"key":"2524_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ijantimicag.2017.01.032","volume":"49","author":"M Madamet","year":"2017","unstructured":"Madamet M, Kounta M, Wade K, Lo G, Diawara S, Fall M, et al. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. Int J Antimicrob Agents. 2017;49:754\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"2524_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12936-016-1622-x","volume":"15","author":"S Menard","year":"2016","unstructured":"Menard S, Tchoufack J, Maffo C, Nsango S, Abate L, Tsapi M, et al. Insight into k13-propeller gene polymorphism and ex vivo DHA-response profile from Cameroonian isolates. Malar J. 2016;15:572.","journal-title":"Malar J"},{"key":"2524_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12936-016-1663-1","volume":"16","author":"B Balikagala","year":"2017","unstructured":"Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, et al. Absence of invivo selection for K13 mutations after artemether\u2013lumefantrine treatment in Uganda. Malar J. 2017;16:23.","journal-title":"Malar J"},{"key":"2524_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12936-018-2233-5","volume":"17","author":"D Ljolje","year":"2018","unstructured":"Ljolje D, Dimbu PR, Kelley J, Goldman I, Nace D, Macaia A, et al. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malar J. 2018;17:84.","journal-title":"Malar J"},{"key":"2524_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"2524_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3201\/eid2401.170864","volume":"24","author":"H Gupta","year":"2018","unstructured":"Gupta H, Macete E, Bulo H, Salvador C, Warsame M, Carvalho E, et al. Drug-resistance polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerg Inf Dis. 2018;24:40\u20138.","journal-title":"Emerg Inf Dis"},{"key":"2524_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12936-016-1099-7","volume":"15","author":"A Adjei","year":"2016","unstructured":"Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai R, Owusu-Age S, et al. Treatment outcomes in a safety observational study of dihydroartemisinin\/piperaquine (Eurartesim\u00ae) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15:43.","journal-title":"Malar J"},{"key":"2524_CR38","volume-title":"HIV\/AIDS and malaria indicator survey 2011\u201312, Tanzania","author":"Tanzania commission for AIDs","year":"2013","unstructured":"Tanzania commission for AIDs. HIV\/AIDS and malaria indicator survey 2011\u201312, Tanzania. Tanzania: Tanzania commission for AIDs; 2013."},{"key":"2524_CR39","unstructured":"Demographic and health survey and malaria indicator survey 2015\u20132016, Dar es salaam, Tanzania. 2016."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-018-2524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-018-2524-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-018-2524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:16:31Z","timestamp":1628612191000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-018-2524-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1186\/s12936-018-2524-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"369"}}